A High-Stakes Alzheimer’s Bet Signals a Shift Toward Precision Tau Therapies
A $1.04 billion licensing deal between a Korean biotech and a global pharmaceutical giant highlights renewed scientific confidence in targeting modified tau proteins, an approach still early but close...